Types segmentation classifies kits according to the underlying molecular methodology, which determines analytical performance, workflow complexity, and capital outlay. Real‑time PCR kits dominate the segment, comprising roughly 60 % of sales, because they deliver high sensitivity, quantitative output, and are compatible with existing laboratory automation. Isothermal amplification kits—principally recombinase polymerase amplification (RPA) and loop‑mediated isothermal amplification (LAMP)—capture about 25 % of the market; their appeal lies in minimal thermal cycling requirements, enabling use in low‑resource settings and point‑of‑care configurations. Next‑generation sequencing (NGS)‑based detection kits represent the remaining 15 %, serving specialized laboratories that integrate pathogen discovery with whole‑genome sequencing for epidemiological tracing. The cost per test varies markedly: real‑time PCR averages $30‑$45, isothermal methods $15‑$25, and NGS platforms exceed $100, reflecting differences in reagent complexity and instrument depreciation. Consequently, the type mix influences overall market valuation, with higher‑margin NGS kits offset by larger volume sales of PCR‑based solutions. Understanding this market taxonomy is essential for manufacturers planning product‑line diversification and for investors assessing revenue streams within the Marburg Virus Nucleic Acid Detection Kit segmentation landscape.
